You are here
Imaging and diagnostics is fast becoming one of the most effective means of detecting cancer. In recent years, CRT has expanded its licensing portfolio in this arena, facilitated by significant investment and funding from Cancer Research UK.
Cancer Research UK and the Engineering and Physical Sciences Research Council (EPSRC) have led an exciting strategic initiative to establish the UK as a world leader in cancer imaging research. After a successful first funding round, Cancer Research UK and EPSRC have jointly committed a further £35 million. This investment will support four large imaging centres across the UK and has already been successful in helping to leverage additional funds from other sources.
The four imaging centres to receive funding are at:
- The University of Oxford;
- The Institute of Cancer Research, London;
- A joint imaging centre between King’s College London and University College London;
- And a new collaboration between the University of Cambridge and University of Manchester.
In addition, cancer imaging research programmes are being funded at institutes including:
- Imperial College
- The University of St Andrews
- Newcastle University
CRT has exclusive commercialisation rights to any IP arising from these centres and programmes. CRT Business Development Managers work closely with the Centre Leaders and Programme Leaders to establish the best commercial model to ensure new discoveries become available to cancer patients.
Cancer Research UK additionally runs the Biomarker Expert Review Panel (BMERP), which reviews and funds biomarker and imaging research from scientists, clinicians or healthcare workers in UK universities, medical schools, hospitals and some research institutions. CRT Business Development Managers are actively involved in the evaluation of BMERP applications and CRT has exclusive commercialisation rights to any IP arising from these programmes.